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Summary Use of cost-effectiveness
acceptabilitycurves, as amethod for
summarisinginformation onuncertaintyin
cost-effectiveness, hasbecome
widespreadwithin applied studies.This
includes several studies inthemental
health field.This editorialuses examples
fromrecentpapers to illustrate howcost-
effectiveness acceptabilitycurves are
constructed, whattheyrepresent and
how they should be interpreted.
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Mounting pressure on healthcare budgets
has led to an increased emphasis on eco-
nomic evidence to guide healthcare policy
and practice decisions. This has meant an
increase in demand for information
concerning the costs and effectiveness of
health technologies in order to determine
their cost-effectiveness. The aim of cost-
effectiveness analysis is to identify efficient
use of scarce healthcare resources, through
identifying the treatments and technologies
that provide the maximum additional
effects per additional unit of resource con-
sumed. The same principles apply to the
treatments, programmes and technologies
that comprise mental health services, and
there is a growing literature concerning
the cost-effectiveness of these various
services.
The cost-effectiveness acceptability
curve (CEAC) is a relatively new concept
that is featuring more frequently in cost-
effectiveness papers within the medical
literature. These curves illustrate the
uncertainty surrounding the estimate
of cost- effectiveness and were developed
as a result of considerable debate regarding
the best way to deal with such uncertainty
(Van Hout et al, 1994; Briggs & Fenn,
1998; Briggs & Gray, 1999; O’Brien &
Briggs, 2002). Since their conception, use
of CEACs has become widespread within
applied studies, including a number in the
mental health field (Bower et al, 2003;
Byford et al, 2003; Haddock et al, 2003;
Miller et al, 2003; Scott et al, 2003;
McCrone et al, 2004). It has thus become
important to understand what CEACs look
like, how they are constructed, what they
represent and how they should be
interpreted. We discuss these issues with
reference to recent papers (from this jour-
nal) that have included CEACs (Haddock
et al, 2003; Scott et al, 2003; McCrone et
al, 2004). We focus on CEACs derived
from comparisons of two interventions.
For evaluations comparing more than two
interventions, see Fenwick et al (2001).
WHATDOES ACEAC LOOK
LIKE?
A CEAC shows the probability that an
intervention is cost-effective compared with
the alternative, given the observed data, for
a range of maximum monetary values (l)
that a decision-maker might be willing to
pay for a particular unit change in out-
come. A typical example of a CEAC is
illustrated in Scott et al (2003: Fig. 1). Their
figure shows the probability that cognitive
therapy is cost-effective compared with
standard clinical management with
antidepressants, for a range of monetary
values that a decision-maker might consider
the maximum acceptable to avoid a
depressive relapse. This range of maxi-
mum monetary values, expressed as £
per depressive relapse avoided, is given
on the x-axis. Given a specified value of
this ‘acceptable’ cost-effectiveness ratio (a
point on the x-axis), the CEAC shows
the probability that the data are
consistent with a true cost-effectiveness
ratio falling below that value (read off the
y-axis).
HOW IS ACEAC
CONSTRUCTED?
Cost-effectiveness acceptability curves were
introduced as an alternative to producing
confidence intervals around incremental
cost-effectiveness ratios (ICERs), which
can be statistically challenging (Van Hout
et al, 1994; Briggs & Fenn, 1998). The
CEAC is derived from the joint distribution
of incremental costs and incremental
effects. The most common technique for
estimating these joint distributions is non-
parametric bootstrapping of the observed
data, although other methods are available
(Van Hout et al, 1994; Lothgren &
Zethraeus, 2000; O’Brien & Briggs,
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Fig.1 Scatter plot showing themean differences in costs and in the primary outcomemeasure (Global
Assessmentof Functioning) from the trial data using1000 bootstrap replicates (differencesbased on cognitive^
behavioural therapyminus control). (Taken from Haddock et al, 2003.)
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2002). A scatter plot of the bootstrapped
incremental costs and effect pairs can be
presented on the incremental cost-
effectiveness plane, as shown in Fig. 1
(taken from Haddock et al, 2003). This
illustrates the uncertainty surrounding the
estimates of expected costs (here in £) and
expected effects (Global Assessment of
Functioning (GAF) scores) associated with
the intervention (cognitive–behavioural
therapy and motivational intervention)
compared with the alternative (routine
treatment).
The incremental cost-effectiveness
plane is divided into four quadrants by
the origin, with each quadrant having a dif-
ferent implication for economic evaluation.
The SE quadrant, with negative costs and
positive effects, represents the position
where the intervention is more effective
and less costly than the alternative
(‘dominates’). Interventions falling in this
quadrant are always considered cost-
effective regardless of the maximum accep-
table ratio (l). The NW quadrant, with
positive costs and negative effects, repre-
sents the position where the intervention
is both more costly and less effective than
the alternative (‘dominated’). Interventions
falling in this quadrant are never considered
cost-effective regardless of l. The NE quad-
rant, with positive costs and positive
effects, and the SW quadrant, with negative
costs and negative effects, involve trade-
offs. These two quadrants represent the
situation where the intervention may be
cost-effective compared with the alterna-
tive, depending upon whether the ICER is
above or below the given value of l.
As illustrated in Fig. 1, the scatter plot
commonly covers all four quadrants,
indicating uncertainty about whether or
not the intervention is cost-effective, and
at what value it is cost-effective. The
purpose of the CEAC is to summarise this
uncertainty.
The CEAC is constructed by plotting
the proportion of the costs and effects pairs
that are cost-effective for a range of values
of l. This proportion is easily identifiable
from the incremental cost-effectiveness
plane as the proportion of points falling
to the south and east of a ray through the
origin with slope equal to l. The process
of constructing a CEAC begins by calculat-
ing this proportion with a ray of slope zero
(equivalent to the x-axis). The process is
repeated numerous times for rays of larger
and larger slopes, up to a maximum value
for l of infinity (equivalent to the y-axis).
Points in the NW quadrant are never
considered cost-effective and therefore
never counted. Points in the SE are always
considered cost-effective and therefore
always counted. As the slope of the ray is
increased from zero to infinity, points in
the NE and SW quadrants may or may
not be considered cost-effective depending
upon the value of l. For more details con-
cerning the shape of the CEAC see Fenwick
et al (2004).
To illustrate this using the example
from Haddock et al (2003), 693 out of
1000 bootstrap re-samples involved cost
savings (fell below the x-axis), hence
69.3% of the costs and effects pairs fell to
the south and east of a ray with slope zero,
and as a result the CEAC crosses the y-axis
at 69.3%. For a ray with a slope of £20 per
point increase in GAF score, the proportion
of the re-samples that were cost-effective
was 70%, and for a ray with a slope of
£655 per point increase in GAF score the
proportion was 90%. In this way, a CEAC
is generated.
HOW IS ACEAC
INTERPRETED?
The CEAC indicates the probability that
the intervention is cost-effective compared
with the alternative, given the data and
for a given value of the maximum accep-
table ratio (l). In the example of Haddock
et al (2003), given a maximum acceptable
ratio of £20 per point increase in GAF
score, the probability that cognitive–
behavioural therapy is cost-effective com-
pared with routine treatment is 0.7. This
is equivalent to stating that, given the data,
there is a 70% chance that the additional
cost of cognitive–behavioural therapy,
compared with routine treatment, is less
than £20 per point increase in GAF score.
Note the comparative nature of both state-
ments. It is not equivalent to stating that
cognitive–behavioural therapy has a 70%
chance of costing less than £20 per point
increase in GAF score.
Care must be taken when interpreting
the information provided by a CEAC. A
CEAC simply presents the probability that
an intervention is cost-effective compared
with the alternative for a range of values
of l. That is, the probability that the ICER
falls below the maximum acceptable ratio.
Statements concerning CEACs should be
restricted to the uncertainty of the estimate
of cost-effectiveness. The information from
a CEAC should not, in general, be used to
make statements about the implementation
of the intervention.
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